As for the antitumour activity, in comparison to free DOX, ApoB/DOX-NLC promoted lower tumour volume, decreased mortality without body loss (in relation to naïve animals), and no cardiac tissue damage after ex vivo analysis. This evidence concerns the gene APOB and neoplasm.